CytoSorbents
CytoSorbents' revenue rose 4.1% to $37 million in fiscal 2025. Its operating margin was −39.8%, up from −46.2% a year earlier. Free cash flow was −$13 million. The diluted share count rose 14.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CytoSorbents does
CytoSorbents makes blood-cleaning devices for hospitals. Its cartridges are filled with tiny porous plastic beads that soak up harmful substances from a patient's blood as it is pumped outside the body through machines hospitals already use, such as dialysis machines and heart-lung machines used in surgery. Doctors use them to remove blood thinners during heart surgery, to lower the risk of severe bleeding, and to remove substances that cause dangerous inflammation in illnesses such as sepsis, burns and liver failure.
Its main product, CytoSorb, is approved in the European Union and sold in more than 70 countries, with more than 300,000 devices used to date; Germany is its biggest market. CytoSorb is not approved in the United States. The company sells through its own sales teams in parts of Europe and through partners and distributors elsewhere. It also sells a cartridge used to treat donor organs before transplant, a version for animals called VetResQ, and a blood pump called PuriFi in some countries.
In the US and Canada it is seeking approval for DrugSorb-ATR, a similar device meant to reduce bleeding in heart bypass patients taking blood thinners. The FDA has given it two Breakthrough Device designations, meant to speed up its review, but it is not yet approved. The company is based in Princeton, New Jersey.
Its biggest risks, as it describes them
- A history of losses and a possible need to raise more money to keep operating.
- The FDA and Health Canada may not approve DrugSorb-ATR, its planned product for North America.
- Losing its European approval, without which it could not sell CytoSorb there.
- Its reliance on Germany, its main market, and on many different distributors elsewhere.
- Hospitals may not get paid enough by insurers and health systems to use its products.
Income statement
CytoSorbents lost money in fiscal 2025: a net loss of $8 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 52 | 22 | 14 | 3 | 6 |
| Debt incl. finance leases | 0 | 5 | 5 | — | 17 |
| Net debt (negative means net cash) | −52 | −17 | −9 | — | 10 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.1x | 0.2x | — | 2.8x |
| Interest coverage | — | — | −84.8x | −12.8x | −7.1x |
| Current ratio | 4.7x | 3.5x | 1.8x | 2.2x | 2.1x |
| Quick ratio | 4.3x | 3.1x | 1.6x | 1.9x | 1.6x |
Cash flow
Projections
Project CytoSorbents' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $269,332 of CytoSorbents shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Phillip P. ChanChief Executive Officer, Director | Bought | 3,774 | $6.00 | $22,644 | Form 4 |
| Sep 15, 2026 | Alan D. SobelDirector | Bought | 2,500 | $6.10 | $15,254 | Form 4 |
| Sep 14, 2026 | Vincent CapponiPresident and COO | Bought | 2,073 | $6.05 | $12,537 | Form 4 |
| Sep 4, 2026 | Phillip P. ChanChief Executive Officer, Director | Bought | 200,000 | $0.35 | $70,000 | Form 4 |
| Jun 15, 2026 | Peter J MarianiChief Financial Officer | Bought | 100,000 | $0.44 | $44,000 | Form 4 |
| Jun 15, 2026 | Phillip P. ChanChief Executive Officer, Director | Bought | 10,333 | $0.43 | $4,443 | Form 4 |
| Jun 12, 2026 | Phillip P. ChanChief Executive Officer, Director | Bought | 251,136 | $0.40 | $100,454 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | — | — |
| Rule of 40 | −81.8% | −26.8% | −29.7% |
| Altman Z'' | −19.25 | −21.30 | −23.50 |
| Accruals ratio | −13.1% | −12.5% | 9.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 9 | — | — |
Compare
Put CytoSorbents side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CytoSorbents | FY25 | 4.1% | −39.8% | −33.8% | — | — | — | |
| ClearPoint Neuro | FY25 | 17.8% | −65.4% | −66.1% | −104.7% | — | 4 | Compare |
| Utah Medical Products | FY25 | −5.8% | 29.6% | 37.2% | 26.8% | −6.0x | 6 | Compare |
| Senseonics | FY25 | 56.9% | −193.8% | −170.9% | — | — | 4 | Compare |
| Pulsenmore | FY25 | 314.3% | — | −82.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 10 | 15 | 22 | 25 | 41 | 43 | 35 | 31 | 36 | 37 |
| Revenue growth | 98.8% | 59.0% | 48.5% | 10.9% | 64.3% | 5.3% | −19.6% | −10.4% | 14.5% | 4.1% |
| Gross profit | 6 | 10 | 15 | 18 | 30 | 32 | 21 | 22 | 25 | 26 |
| Research and development | 4 | 3 | 8 | 12 | 9 | 16 | 15 | 16 | — | — |
| Operating income | −12 | −10 | −16 | −19 | −10 | −23 | −32 | −32 | −16 | −15 |
| Net income | −12 | −8 | −17 | −19 | −8 | −25 | −33 | −29 | −21 | −8 |
| Diluted EPS (US$) | −0.46 | −0.32 | −0.56 | −0.60 | −0.20 | −0.57 | −0.75 | −0.65 | −0.38 | −0.13 |
| Diluted shares (millions) | 25 | 28 | 31 | 32 | 39 | 43 | 44 | 45 | 54 | 62 |
| Cash flow | ||||||||||
| Cash from operations | −7 | −6 | −11 | −17 | −6 | −14 | −28 | −22 | −14 | −12 |
| Capital expenditure | 0 | 1 | 1 | 1 | 1 | 4 | 6 | 0 | 0 | 0 |
| Free cash flow | −7 | −7 | −12 | −17 | −6 | −18 | −34 | −22 | −15 | −13 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 3 | 4 | 2 | 4 | 4 | 3 | 4 | 4 | 3 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 5 | 17 | 22 | 12 | 71 | 52 | 22 | 14 | 3 | 6 |
| Debt incl. finance leases | 5 | 10 | 10 | 15 | 0 | 0 | 5 | 5 | — | 17 |
| Total assets | 10 | 24 | 34 | 27 | 90 | 90 | 63 | 53 | 47 | 44 |
| Total liabilities | 8 | 14 | 17 | 24 | 11 | 27 | 28 | 30 | 36 | 38 |
| Shareholders' equity | 1 | 10 | 17 | 3 | 79 | 63 | 35 | 24 | 11 | 6 |
| Margins and ratios | ||||||||||
| Gross margin | 58.5% | 63.6% | 66.7% | 70.5% | 73.0% | 74.4% | 59.8% | 70.6% | 69.9% | 71.5% |
| Operating margin | −120.6% | −65.0% | −69.2% | −76.0% | −25.3% | −52.7% | −90.9% | −102.8% | −46.2% | −39.8% |
| Net margin | −123.5% | −55.8% | −76.5% | −77.2% | −19.1% | −56.9% | −94.6% | −94.1% | −58.2% | −22.1% |
| Free cash flow margin | −72.1% | −49.2% | −51.1% | −70.0% | −15.4% | −40.9% | −98.9% | −71.4% | −41.3% | −33.8% |
| Rule of 40 (growth + FCF margin) | 26.7% | 9.8% | −2.6% | −59.1% | 48.9% | −35.6% | −118.6% | −81.8% | −26.8% | −29.7% |
| Return on capital | −543.4% | −395.0% | −331.0% | −279.0% | −116.8% | −197.1% | −173.7% | −154.7% | — | — |
| Return on equity | −210.4% | −145.9% | −126.6% | −189.3% | −19.0% | −34.6% | −67.0% | −99.4% | −119.8% | −96.4% |
| Return on assets | −112.3% | −50.1% | −59.0% | −62.6% | −13.4% | −27.4% | −43.0% | −50.3% | −41.3% | −17.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |